Integrated genomic analysis of clear cell ovarian cancers identified PRKCI as a potential therapeutic target

Abstract

Clear cell ovarian cancer (CCOC) is an epithelial ovarian cancer histotype with unique pathologic, biologic and clinical features. Despite its worse prognosis than serous ovarian cancer (SOC), the genomic landscape of CCOC is less well defined. Integrated genomic analysis of CCOC allows the identification of potential therapeutic targets to improve the treatment of this tumor. Using comparative genomic hybridization and gene expression profiling, we have screened 12 CCOC cell lines and 40 tumors to identify 45 amplified and overexpressed genes. Pathways analysis of these genes identified 19 genes with cancer-related functions. Of these, PRKCI is one of the most frequently amplified and overexpressed genes and its expression induced cancer cell proliferation and migration/invasion <i>in vitro</i> as well as tumor growth <i>in vivo</i>. Targeting PRKCI by small molecule inhibitor, sodium aurothiomalate (ATM), significantly reduced the <i>in vivo</i> tumor growth and may be a new therapeutic strategy to improve the treatment of CCOC.